Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Brain scans with a tau tracer in Alzheimer's disease and related conditions

Tests a tracer, [18F]NIDF, to image tau protein in adult brains.

Key facts

Who runs it
Tianjin Medical University
Where
Hefei, Qingdao, and Tianjin, ChinaSee the 3 sites
Trial code
Registry title
[18F]NIDF PET Imaging in Tau-related Diseases
Status
Recruiting
People taking part
20 people, planned
Started
1 Nov 2025
Expected to end
1 Dec 2030
Type of study
Observational, 2 groups
Record updated
8 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 90 who are healthy or have probable Alzheimer's disease or dementia from other causes, to test a brain scan tracer called [18F]NIDF.

Age
18 to 90 years old
Sex
All sexes can join.
Disease stage
Healthy participants, or patients with probable Alzheimer's disease or dementia due to other causes. Clinical results must support a diagnosis of neurodegeneration, with no sign of other neurological diseases.
Earlier treatment
People who received an experimental drug or device within 1 month cannot join.

Main reasons for not taking part

  • Allergy to [18F]NIDF or any of its excipients
  • Cannot give written informed consent and has no legal representative to give it
  • Unwilling or unable to have PET scan tracer injections
  • Other serious neurological, stomach and gut, heart, liver, kidney, blood, cancer, hormone, lung or immune diseases
  • Currently pregnant or breastfeeding

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Between 18 and 90 years old
  • No gender limitation
  • Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases
  • Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes
  • Informed consent signed in person by the subject or his legal guardian or caregiver

Who cannot take part

  • Received an experimental drug or device within 1 month (whose efficacy or safety is unclear)
  • Has allergy to [18F]NIDF or any of its excipients
  • Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer)
  • Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases
  • Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent
  • Unwilling or unable to undergo PET scans tracer injections
  • Women who are currently pregnant or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Where in China

  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaContact: Qiang Xie, PhDTaking people
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Guangjie Yang, MDTaking people
  • Tianjin Medical University General HospitalTianjin, ChinaContact: Ying Wang, MDTaking people

About the trial

What the trial wants to find out

In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents.

Read full original descriptionShow less

This clinical research project aims to visualize abnormal tau pathology in the living human brain using [18F]NIDF PET imaging. [18F]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of [18F]NIDF PET imaging in human subjects.

The 2 groups in the trial

  • Healthy participants

    Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of \[18F\]NIDF followed by a PET/CT scan.

  • Patients with cognitive impairment

    Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of \[18F\]NIDF followed by a PET/CT scan.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
[18F]NIDF PET Imaging in Tau-related Diseases
Plain-language title
Brain scans with a tau tracer in Alzheimer's disease and related conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07306598, who can take part
Record updated
8 September 2026